# DualityBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dualitybio

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.dualitybiologics.com
- Total disclosed funding: $120M
- Latest round: Series B (May 20, 2021)
- Investors on record: 9

## About

Founded in 2020 and based in Suzhou, China, Duality Biologics operates as a provider of innovative molecular drug that provides bispecific antibody drugs. The company has branch offices in Shanghai and Beijing, and has cooperated with 3SBio Inc., BioNTech, etc. It has acquired FTD, ODD, IND and other certifications. The founder, chairman of the board and CEO, Zhu Zhongyuan, is a doctor of the University of Massachusetts Medical School, and has worked in Mingxin Capital, SIG Asia Investment Fund, etc. In April 2025, it raised CNY 1.64 billion in an IPO, selling 17.33 million shares at CNY 94.6 per share on the Hong Kong Stock Exchange.

The company has developed DITAC, DIBAC, DIMAC, DUPAC and other technology platforms. Products include dual-antibody ADC, new mechanism-loaded ADC and autoimmune ADC. Its technologies and products can be used to treat cancer and autoimmune diseases.

The company generates revenue by providing dual-antibody ADC, new mechanism-loaded ADC and autoimmune ADC.

## Funding rounds

- Series B, May 20, 2021, $90M — Lilly Asia Ventures, Oriza Holdings, Green Pine Capital Partners, Huagai Capital, WuXi Biologics (Cayman) Inc., Yinglian Health Industry Fund, NRL Capital
- Series A, Dec 31, 2020, $30M — 6 Dimensions Capital, King Star Capital, WuXi Biologics (Cayman) Inc.

## Investors

- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A
- King Star Capital — Series A
- WuXi Biologics (Cayman) Inc. — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series B
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series B
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series B
- Yinglian Health Industry Fund — Series B
- NRL Capital (https://capitalatlas.ai/funds/nrl-capital) — Series B